Skip to main content

Advertisement

SpringerLink
Log in

In situ activation of mouse macrophages and therapy of spontaneous renal cell cancer metastasis by liposomes containing the lipopeptide CGP 31362

  • Original articles
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Summary

We determined whether the intravenous administration of multilamellar vesicle liposomes (MLV) containing a lipopeptide analogue of a fragment from the cell wall of gram-negative bacteria (CGP 31 362) can render BALB/c mouse alveolar macrophages tumoricidal in situ and reduce the incidence of spontaneous lung metastasis of syngeneic renal carcinoma (RENCA) cells. Alveolar macrophages (a) incubated in vitro with MLV containing CGP 31 362 (MLV-31 362) and (b) harvested from mice injected i.v. with MLV-31 362 were rendered cytotoxic against the RENCA cells. Maximum cytotoxic activity of the macrophages was induced by injecting 5 µmol MLV consisting of 250 mg phospholipids and 0.5 mg CGP 31 362. The single i.v. injection of 5 µmol MLV-31 362 produced activation of macrophages that lasted for up to 4 days. Repeated i. v. injections of MLV-31 362 produced a continuous antitumor activity in alveolar macrophages. To study the lipopeptide's effects on metastasis, we injected the left kidneys of BALB/c mice with RENCA cells. The kidney with growing tumor was resected 10 days later and, after a further 2 days, groups of mice were injected i.v. with MLV-31 362 or with MLV-HBSS (twice weekly for 3 weeks). Treatment with MLV-31 362 significantly decreased the median number of spontaneous lung metastases. These data demonstrate that the systemic administration of MLV-31 362 can activate murine lung macrophages in situ and reduce the incidence of spontaneous RENCA lung metastases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Adams DO, Kao K-J, Farb R, Pizzo SV (1980) Effector mechanisms of cytolytically activated macrophages: II. Secretion of a cytolytic factor by activated macrophages and its relationship to secreted neural proteases. J Immunol 124: 293

    Google Scholar 

  2. Brodt P, Blore J, Phillips NC, Munzer JS, Rioux JD (1989) Inhibition of murine hepatic tumor growth by liposomes containing a lipophilic muramyl dipeptide. Cancer Immunol Immunother 28: 54

    Google Scholar 

  3. Creaven PJ, Cowens JW, Brenner DE, Dadey BM, Han T, Huben R, Karakousis C, Frost H, LeSher D, Hanagan J, Andrejcio K, Cushman MK (1990) Initial clinical trial of the macrophage activator muramyl tripeptide-phosphatidylethanolamine encapsulated in liposomes in patients with advanced cancer. J Biol Response Mod 9: 492

    Google Scholar 

  4. Fidler IJ (1981) The in situ induction of tumoricidal activity in alveolar macrophages by liposomes containing muramyl dipeptide is a thymus-independent process. J Immunol 127: 1719

    Google Scholar 

  5. Fidler IJ (1985) Macrophages and metastasis — a biological approach to cancer therapy: presidential address. Cancer Res 45: 4714

    Google Scholar 

  6. Fidler IJ (1988) Targeting of immunomodulators to mononuclear phagocytes for therapy of cancer. Adv Drug Delivery Rev 2: 69

    Google Scholar 

  7. Fidler IJ, Raz A, Fogler WE, Kirsh R, Bugelski P, Poste G (1980) The design of liposomes to improve delivery of macrophageaugmenting agents to alveolar macrophages. Cancer Res 40: 4460

    Google Scholar 

  8. Fidler IJ, Sone S, Fogler WE, Barnes ZL (1981) Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. Proc Natl Acad Sci USA 78: 1680

    Google Scholar 

  9. Fidler IJ, Sone S, Fogler WE, Smith D, Braun DG, Tarcsay L, Gisler RJ, Schroit AJ (1982) Efficacy of liposomes containing a lipophilic muramyl dipeptide derivative for activating the tumoricidal properties of alveolar macrophages in vivo. J Biol Response Mod 1: 43

    Google Scholar 

  10. Fidler IJ, Fogler WE, Tarcsay L, Schumann G, Braun DG, Schroit AJ (1983) Systemic activation of macrophages and treatment of cancer metastases by liposomes containing hydrophilic or lipophilic muramyl dipeptide. Immunopharmacol 2: 253

    Google Scholar 

  11. Fidler IJ, Fogler WE, Kleinerman ES, Saiki I (1985) Abrogation of species specificity for activation of tumoricidal properties in macrophages by recombinant mouse or human gamma interferon encapsulated in liposomes. J Immunol 135: 4289

    Google Scholar 

  12. Fidler IJ, Jessup JM, Fogler WE, Staerkel R, Mazumder A (1986) Activation of tumoricidal properties in peripheral blood monocytes of patients with colorectal carcinoma. Cancer Res 44: 994

    Google Scholar 

  13. Fidler IJ, Fan D, Ichinose Y (1989) Potent in situ activation of murine lung macrophages and therapy of melanoma metastases by systemic administration of liposomes containing muramyltripeptide phosphatidylethanolamine and interferon gamma. Invasion Metastasis 9: 75

    Google Scholar 

  14. Fidler IJ, Nii A, Utsugi T, Brown D, Bakouche O, Kleinerman ES (1990) Differential release of TNF-α, IL 1, and PGE2 by human blood monocytes subsequent to interaction with different bacterial derived agents. Lymphokine Res 9: 449

    Google Scholar 

  15. Fogler WE, Fidler IJ (1986) The activation of tumoricidal properties in human blood monocytes by muramyl dipeptide requires specific intracellular interaction. J Immunol 136: 2311

    Google Scholar 

  16. Hibbs JB, Taintor RR, Vavrin Z (1987) Macrophage cytotoxicity: role forl-arginine deiminase and imino nitrogen oxidation to nitrate. Science 235: 473

    Google Scholar 

  17. Hudson MM, Snyder JS, Jaffe N, Kleinerman ES (1988) In vitro and in vivo effect of Adriamycin therapy on monocyte activation by liposome-encapsulated immunomodulators. Cancer Res 48: 5256

    Google Scholar 

  18. Ichinose Y, Bakouche O, Tsao JY, Fidler IJ (1988) Tumor necrosis factor and IL-1 associated with plasma membranes of activated human monocytes lyse monokine-sensitive but not monokine-resistant tumor cells whereas viable activated monocytes lyse both. J Immunol 141: 512

    Google Scholar 

  19. Key ME, Talmadge JE, Fogler WE, Bucana CD, Fidler IJ (1982) Isolation of tumoricidal macrophages from lung melanoma metastases of mice treated systemically with liposomes containing a lipophilic derivative of muramyl dipeptide. J Natl Cancer Inst 69: 1189

    Google Scholar 

  20. Kleinerman ES, Murray JL, Snyder JS, Cunningham JE, Fidler IJ (1989) Activation of tumoricidal properties in monocytes from cancer patients following intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine. Cancer Res 49: 4665

    Google Scholar 

  21. Lachman LB, Dinarello CA, Llansa ND, Fidler IJ (1986) Natural and recombinant human interleukin 1-β is cytotoxic for human melanoma cells. J Immunol 136: 3098

    Google Scholar 

  22. MacEwen EG, Kurzman ID, Rosenthal RC, Smith BW, Manley PA, Roush JK, Howard PE (1989) Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. J Natl Cancer Inst 81: 935

    Google Scholar 

  23. Mehta K, Lopez-Berestein G, Hersh EM, Juliano RL (1982) Uptake of liposomes and liposome-encapsulated muramyl dipeptide by human peripheral blood monocytes. J Reticuloendothel Soc 32: 155

    Google Scholar 

  24. Murphy GP, Hrushesky WJ (1973) A murine renal cell carcinoma. J Natl Cancer Inst 50: 130

    Google Scholar 

  25. Murray JL, Kleinerman ES, Cunningham JE, Tatom JR, Andrejcio K, Lepe-Zuniga J, Lamki LM, Rosenblum MG, Frost H, Gutterman JU, Fidler IJ (1989) Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine [MTP-PE (CGP 19 835A)] in cancer patients. J Clin Oncol 7: 915

    Google Scholar 

  26. Nathan CF, Silverstein SC, Brukner LH, Cohn ZA (1979) Extracellular cytolysis by activated macrophages and granulocytes: II. Hydrogen peroxide as a mediator of cytotoxicity. J Exp Med 149: 100

    Google Scholar 

  27. Nii A, Utsugi T, Fan D, Denkins Y, Pak C, Brown D, van Hoogevest P, Fidler IJ (1991) Development of liposomes containing a new lipopeptide CGP 31 362 for efficient activation of tumoricidal properties in monocytes and macrophages. J Immunother (in press)

  28. Onozaki K, Matsushima K, Aggarwal BB, Saito T, Oppenheim JJ (1985) Human interleukin-1 is a cytocidal factor for several tumor cell lines. J Immunol 135: 3862

    Google Scholar 

  29. Phillips NC, Tsao M (1989) Inhibition of experimental liver tumor growth in mice by liposomes containing a lipophilic muramyl dipeptide. Cancer Res 49: 936

    Google Scholar 

  30. Phillips NC, Mora ML, Chedid L, Lefrancier P, Bernard JM (1985) Activation of tumoricidal activity of experimental metastases by freeze-dried liposomes containing a new lipophilic muramyl dipeptide derivative. Cancer Res 45: 128

    Google Scholar 

  31. Raz A, Fogler WE, Fidler IJ (1979) The effect of experimental condition on the expression of in vitro mediated tumor cytotoxicity mediated by murine macrophages. Cancer Immunol Immunother 7: 157

    Google Scholar 

  32. Saiki I, Fidler IJ (1985) Synergistic activation by recombinant mouse interferon-γ and muramyl dipeptide of tumoricidal properties in mouse macrophages. J Immunol 135: 684

    Google Scholar 

  33. Salup RR, Herberman RB, Wiltrout RH (1985) Role of natural killer activity in the development of spontaneous metastasis in murine renal cancer. J Urol 134: 1236

    Google Scholar 

  34. Schroit AJ, Fidler IJ (1982) Effects of liposome structure and lipid composition on the activation of the tumoricidal properties of macrophages by liposomes containing muramyl dipeptide. Cancer Res 42: 161

    Google Scholar 

  35. Schroit AJ, Hart IR, Madsen J, Fidler IJ (1983) Selective delivery of drugs encapsulated in liposomes: natural targeting to macrophages involved in various disease states. J Biol Response Mod 2: 97

    Google Scholar 

  36. Sone S, Fidler IJ (1981) In vitro activation of tumoricidal properties in rat alveolar macrophages by synthetic muramyl dipeptide encapsulated in liposomes. Cell Immunol 57: 42

    Google Scholar 

  37. Sone S, Tandon P, Utsugi T, Ogawara M, Shimizu E, Nii A, Ogura T (1986) Synergism of recombinant interferon gamma with liposomeencapsulated muramyl tripeptide in activation of the tumoricidal properties of human monocytes. Int J Cancer 38: 495

    Google Scholar 

  38. Sone S, Utsugi T, Tandon P, Ogawara M (1986) A dried preparation of liposomes containing muramyl tripeptide phosphatidylethanolamine as a potent activator of human blood monocytes to the antitumor state. Cancer Immunol Immunother 22: 191

    Google Scholar 

  39. Talmadge JE, Lenz BF, Klabansky R, Simon R, Rigs C, Guo S, Oldham RK, Fidler IJ (1986) Therapy of autochthonous skin cancers in mice with intravenously injected liposomes containing muramyl tripeptide. Cancer Res 46: 1160

    Google Scholar 

  40. Urba WJ, Hatmann LC, Longo DL, Steis RG, Smith II JW, Kedar I, Creekmore S, Sznol M, Conlon K, Kopp WC, Huber C, Herold M, Alvord WG, Snow S, Clark JW (1990) Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamine. Cancer Res 50: 2979

    Google Scholar 

  41. Utsugi T, Nii A, Fan D, Pak CC, Denkins Y, van Hoogevest P, Fidler IJ (1991) Comparative efficacy of liposomes containing synthetic bacterial cell wall analogues for tumoricidal activation of monocytes and macrophages. Cancer Immunol Immunother 33: 285–292

    Google Scholar 

  42. van Hoogevest P, Fankhauser P (1989) An industrial liposomal dosage form for muramyl-tripeptide-phosphatidylethanolamine (MTP-PE). In: Lopez-Berestein G, Fidler IJ (eds). Liposomes in the therapy of infectious diseases and cancer. Liss, New York, p 453

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cell Biology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 173, 77030, Houston, Texas, USA

    Teruhiro Utsugi, Colin P. N. Dinney, Jerald J. Killion & Isaiah J. Fidler

Authors
  1. Teruhiro Utsugi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Colin P. N. Dinney
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jerald J. Killion
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Isaiah J. Fidler
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Utsugi, T., Dinney, C.P.N., Killion, J.J. et al. In situ activation of mouse macrophages and therapy of spontaneous renal cell cancer metastasis by liposomes containing the lipopeptide CGP 31362. Cancer Immunol Immunother 33, 375–381 (1991). https://doi.org/10.1007/BF01741597

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01741597

Key words

Search

Navigation